Suggestions
Ettore Biagi
Global Clinical Development BMS/Celgene
Ettore Biagi is a Director and Senior Clinical Trial Physician at Bristol Myers Squibb (BMS), based in Neuchâtel, Switzerland. He has a robust background in pediatric medicine and hemato-oncology, having been a practicing pediatrician since 2000. His expertise includes extensive experience in clinical trials, particularly in the development of therapies for hematologic malignancies and solid tumors.
Education and Career
- Medical Degree (MD): Biagi has a medical degree and holds a PhD, indicating a strong foundation in both clinical practice and research.
- Clinical Trials: He is involved in designing and overseeing clinical trials, ensuring that new therapies are evaluated effectively for safety and efficacy.
Contributions
Biagi has contributed to various research publications and clinical studies, particularly focusing on innovative treatments such as CAR T-cell therapies. His work at BMS aligns with the company's commitment to advancing cancer treatment options through rigorous scientific research.
Professional Presence
He maintains an active professional presence on platforms like LinkedIn, where he shares insights related to clinical development and oncology research. His LinkedIn profile can be found under the username ettore-biagi-207ab420 .1
Ettore Biagi’s role at Bristol Myers Squibb exemplifies the intersection of clinical expertise and research innovation, contributing significantly to advancements in cancer treatment.
Highlights
Recently published in Leukemia, 2024. Free download available!
Rational combinatorial targeting by adapter CAR-T-cells (AdCAR-T) prevents antigen escape in acute myeloid leukemia
Atar, D; et al
AML intratumoral heterogeneity in antigen expression translates into antigen escape and therapy failure to monotargeted CAR-T therapy. High antigen expression variability is observed not only across different patient samples but also among leukemic cells of the same patient suggesting the necessity of multiplexed targeting approaches. To address this need, the authors present a modular Adapter CAR (AdCAR) platform, enabling precise qualitative and quantitative control over CAR-T-cell function, showing highly efficient and target-specific activity for newly generated adapter molecules (AMs) against CD33, CD38, CD123, CD135 and CD371.
AML immunotherapy still represents a challenging field of investigation. Multitarget CAR platforms may represent an innovative tool to overcome AML heterogeneity. Clinical translation is now warranted.
Recently published in Nat Commun, 2024 vol. 15(1) p. 7141
CAR T-cell-mediated delivery of bispecific innate immune cell engagers for neuroblastoma
Pascual-Pasto, et al
Novel chimeric antigen receptor design is warranted to both target tumor-specific antigens and also boost innate immune cells such as NK. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment infiltrated by CD16a-expressing innate immune cells. T-cells were engineered to express a GPC2-directed CAR and simultaneously secrete a bispecific innate immune cell engager (BiCE) targeting both GD2 and CD16a. A CAR.BiCE strategy should be considered for tumor histologies where antigen escape limits CAR efficacy, especially for solid tumors like neuroblastoma that are infiltrated by innate immune cells.
This new CAR construct pave the way to investigate more innovative immune cell engineering to boost T cell activity. Clinical applications are now warranted.
